Previous 10 | Next 10 |
2023-11-01 13:45:35 ET Summary CRISPR Therapeutics AG and Vertex Pharmaceuticals are one step closer to gaining approval for their CRISPR/Cas9 gene editing therapy for Sickle Cell Disease and beta thalassemia. An FDA Advisory Committee raised a few concerns about the safety of the...
2023-11-01 12:07:53 ET Summary CRISPR Therapeutics' exa-cel gene therapy for Sickle Cell Disease faces potential regulatory tripwires, which could impact FDA approval and the company's market valuation. Financially, CRISPR is in a robust position with $1.76B in liquid assets but g...
2023-11-01 08:26:46 ET More on CRISPR Therapeutics Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy CRISPR Therapeutics: CEO Targets $25bn Valuation - Exa-Cel Approval Is First Step Crispr Therapeutics: The Chance To Load Up Is Finally...
2023-11-01 05:24:33 ET Related stories: Yum China Holdings, Inc. (YUMC) Q3 2023 Earnings Call Transcript Yum China Holdings, Inc. 2023 Q3 - Results - Earnings Call Presentation Paycom Software, Inc. (PAYC) Q3 2023 Earnings Call Transcript For further details ...
-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)- ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration’s (FDA)...
2023-10-31 17:22:00 ET More on CRISPR, Vertex Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy Vertex Pharmaceuticals Deserves Its Monopoly Premium Indeed CRISPR Therapeutics: CEO Targets $25bn Valuation - Exa-Cel Approval Is First Ste...
2023-10-31 12:46:31 ET More on Eli Lilly Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated Eli Lilly: Do Not Chase This Stock Over The Cliff ...
2023-10-31 07:48:17 ET More on CRISPR, Vertex, etc. Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy Vertex Pharmaceuticals Deserves Its Monopoly Premium Indeed CRISPR Therapeutics: CEO Targets $25bn Valuation - Exa-Cel Approval Is Fir...
ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock. ...
2023-10-27 16:41:11 ET More on CRISPR Therapeutics, Vertex Pharmaceuticals, etc. Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy Vertex Pharmaceuticals Deserves Its Monopoly Premium Indeed CRISPR Therapeutics: CEO Targets $25bn Valuat...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website:
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...